The RAF proteins take centre stage

Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.
Nature Reviews Molecular Cell Biology (Impact Factor: 36.46). 12/2004; 5(11):875-85. DOI: 10.1038/nrm1498
Source: PubMed

ABSTRACT Since their discovery over 20 years ago, the RAF proteins have been intensely studied. For most of that time, the focus of the field has been the C-RAF isoform and its role as an effector of the RAS proteins. However, a report that implicates B-RAF in human cancer has highlighted the importance of all members of this protein kinase family and recent studies have uncovered intriguing new data relating to their complex regulation and biological functions.

Download full-text


Available from: Maria Karasarides, Aug 14, 2015
  • Source
    • "By contrast, LS mutants behaved as loss-of-function mutations of SHP2, impairing ERK activation [10] [11] [12]. Within the heart, ERK1/2 are activated at the plasma membrane by Raf-1, followed by activation of small G protein Ras [13]. Harris et al. showed that dominant negative Raf-1 inhibited ERK1/2 activation in transgenic mice, which were resistant to hypertrophic stress but developed significant cardiomyocyte apoptosis [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitogen-activated protein kinases (MAPKs) are involved in the regulation of cardiac hypertrophy and myocyte survival. Extracellular signal regulated protein kinase 1 and 2 (ERK1/2) are key components in the MAPKs signaling pathways. Dysfunction of ERK1/2 in congenital heart diseases (Noonan syndrome and LEOPARD syndrome) leads to cardiac hypertrophy. ERK2 contributes 70% of protein content to total ERK1/2 content in myocardium, however, the specific role of ERK2 in regulating cardiac hypertrophy is yet to be further defined. To investigate the specific role of ERK2 played in the cardiomyocytes, we generated and examined mice with cardiomyocyte-specific deletion of the erk2 gene (ERK2cko mice). Following short-term pathological hypertrophic stresses, the mutant mice showed attenuated hypertrophic remodeling characterized by a blunted increase in cross-sectional area of individual myocytes, downregulation of hypertrophic foetal gene markers (ANP and BNP), and less interstitial fibrosis. However, increased cardiomyocyte apoptosis was observed. Upon prolonged stimulation, ERK2cko mice developed deterioration in cardiac function. However, absence of ERK2 did not affect physiological hypertrophy induced by 4 weeks of swimming exercise. These results revealed an essential role for ERK2 in cardiomyocytes in the development of pathological hypertrophic remodeling and resistance to cell death.
    Journal of Molecular and Cellular Cardiology 07/2014; 72(100). DOI:10.1016/j.yjmcc.2014.03.002 · 5.22 Impact Factor
  • Source
    • "pathway blocks the growth of melanoma cells harboring an oncogenic BRAF mutation and thus represents an attractive therapeutic target (Wellbrock et al., 2004; Miller and Mihm, 2006; Tsao et al., 2012). Oncogenic NRAS is capable of activating multiple downstream pathways, including BRAF- MEK-ERK, all of which are thought to play an important role in NRAS driven oncogenesis (Downward, 2003; Karnoub and Weinberg, 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: eLife digest Cancer is a leading cause of death worldwide, and although cancer can have many causes, mutations to a small number of genes are often responsible for a large number of cancer cases. For example, about 70% of cases of the deadliest form of skin cancer have mutations in two specific genes. Many cancer-causing genes are regulated by small RNA molecules that impede the function of other genes by blocking the machinery that turns a gene into a functional protein. However, until recently there was a limited understanding of the role of these microRNAs in the skin cancers caused by the most common mutations. Now, Forloni et al. have looked at all the microRNAs present in cells carrying a mutated form of the one of these genes, and compared these with the microRNAs found in healthy cells. A microRNA, called miR-146a, was discovered to be much more common in the cancer cells. Moreover, production of this microRNA was increased by the two cancer-causing mutations. Forloni et al. found that increasing production of this microRNA caused human skin cancer cells to grow faster, and also caused tumors to develop in mice. Reducing the level of miR-146a had the opposite effect. Forloni et al. also looked at cancer cells taken from individuals at different stages of skin cancer and found that, as the disease progresses, an unprocessed form of miR-146a tends to acquire a mutation, which leads to much higher levels of the active, processed form of miR-146a in the cancer cells. High levels of miR-146a also switched off a gene that encodes for a protein that, in turn, switches off a protein called NOTCH that is linked to skin cancer. As such, excess miR-146a actually increases the activation of the NOTCH protein. These results led Forloni et al. to test if delivering drugs that block the production of miR-146a by inhibiting skin cancer-causing genes, along with other drugs that inhibit the Notch signaling pathway, could be more effective than treatment with either drug on its own. The combined treatment was very effective against human skin cancer cells and could represent a promising development in the treatment of this disease. DOI:
    eLife Sciences 02/2014; 3:e01460. DOI:10.7554/eLife.01460 · 8.52 Impact Factor
  • Source
    • "The RAS-RAF-MEK-ERK signaling pathway is key for a variety of cellular functions including controlling cell proliferation and survival (Baccarini, 2005; Wellbrock et al., 2004). Dysregulation of this pathway is also important in cancer with most tumors exhibiting mutations in RAS and/or RAF (Brose et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although RAF kinases are critical for controlling cell growth, their mechanism of activation is incompletely understood. Recently, dimerization was shown to be important for activation. Here we show that the dimer is functionally asymmetric with one kinase functioning as an activator to stimulate activity of the partner, receiver kinase. The activator kinase did not require kinase activity but did require N-terminal phosphorylation that functioned allosterically to induce cis-autophosphorylation of the receiver kinase. Based on modeling of the hydrophobic spine assembly, we also engineered a constitutively active mutant that was independent of Ras, dimerization, and activation-loop phosphorylation. As N-terminal phosphorylation of BRAF is constitutive, BRAF initially functions to activate CRAF. N-terminal phosphorylation of CRAF was dependent on MEK, suggesting a feedback mechanism and explaining a key difference between BRAF and CRAF. Our work illuminates distinct steps in RAF activation that function to assemble the active conformation of the RAF kinase.
    Cell 08/2013; 154(5):1036-46. DOI:10.1016/j.cell.2013.07.046 · 33.12 Impact Factor
Show more